Ionis Pharmaceuticals, Inc. ( NASDAQ: IONS) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT ...

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab ...

Whitbread PLC announced the purchase of 34,543 of its ordinary shares as part of its ongoing share buy-back program. The shares were acquired at prices ranging from 3,095.00 to 3,118.00 pence per ...

CRH plc has announced the acquisition and subsequent cancellation of its ordinary shares in the United States as part of a share buyback program. This initiative, which aims to repurchase up to ...